Last reviewed · How we verify
Ultra-Rapid Lispro
Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas.
Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas. Used for Treatment of diabetes mellitus.
At a glance
| Generic name | Ultra-Rapid Lispro |
|---|---|
| Also known as | LY900014, Insulin lispro |
| Sponsor | Eli Lilly and Company |
| Drug class | rapid-acting insulin analog |
| Target | insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the insulin receptor on the surface of pancreatic beta cells, triggering a cascade of intracellular signaling events that ultimately lead to insulin release. This results in a rapid increase in blood glucose levels, which helps to lower blood sugar levels in people with diabetes.
Approved indications
- Treatment of diabetes mellitus
Common side effects
- Hypoglycemia
Key clinical trials
- Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes (NA)
- Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System (PHASE4)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Closing the Loop in Adults With Type 1 Diabetes (CLEAR) (NA)
- Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study) (NA)
- Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4) (NA)
- A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes (PHASE3)
- A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |